{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.7","upperLimit":"24.5","value":"16.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"title":"CLL/SLL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.8","upperLimit":"58.6","value":"46.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"WM"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.0","upperLimit":"41.5","value":"28.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"MCL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"43.7","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"MZL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"35.5","value":"18.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"FL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.9","upperLimit":"39.5","value":"24.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"DLBCL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"45.4","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"RT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"48.4","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"HCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"}],"units":"Participants"}],"description":"CRR is defined as the percentage of participants who achieve a complete response, as assessed by the investigator. For CLL/SLL, CRR includes CRi or better. For WM, CRR includes very good partial response (VGPR) or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).","dispersionType":"95% Confidence Interval","groups":[{"description":"The dose regimens from Part 1 (40 mg, 80 mg, 160 mg QD, 160 mg BID and 320 mg QD) and Part 2 (160 mg BID and 320 mg QD) were evaluated in different disease types. Efficacy evaluations are reported by disease type for Parts 1 and 2 combined, as pre-specified in the statistical analysis plan.","id":"OG000","title":"Part 1 and Part 2: Overall"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Set consists of all participants who received at least one dose of zanubrutinib; for WM, participants also must have a baseline IgM (or M-protein) ≥ 5 g/L and no prior exposure to a BTK inhibitor.","reportingStatus":"POSTED","timeFrame":"Up to 6 years and 7 months","title":"Part 1 and Part 2: Complete Response Rate (CRR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}